CCELESTE BUILD

CJC 1295 + Ipamorelin peptide combination for endocrine research

CJC NO DAC + Ipamorelin is a combination of two research peptides used in scientific research to study the endogenous release of growth hormone (GH) and IGF-1. CJC-1295 without DAC (also known as Modified GRF (1–29)) functions as a GHRH analog, while Ipamorelin is a growth hormone secretagogue with a GHRP-like mechanism of action. In research designs, these peptides are often combined to analyze potential synergistic effects on GH secretion.

Cceleste CJC 1295 + Ipamorelin is part of the specialized range of research peptides within the category of endocrine signaling agents . The product is intended exclusively for professional laboratory research, such as in vitro studies, R&D, assay development, and method validation.

Scientific background

In research models, CJC-1295 without DAC stimulates the pituitary gland via the GHRH receptor, leading to pulsatile growth hormone release. Ipamorelin activates GH release via an alternative receptor pathway related to GHRP mechanisms. Due to these different targets, the combination is being investigated to understand the effect of simultaneous GHRH and GHRP stimulation on endocrine profiles.

In the literature, this combination is used to better map hormonal dynamics, feedback mechanisms, and downstream effects on IGF-1 within controlled research settings.

Possible research areas and effects

Within strictly controlled study designs, various research observations have been described for CJC 1295 + Ipamorelin. These findings serve solely as scientific context:

• GH and IGF-1 secretion – analysis of pulse frequency and amplitude of growth hormone release and associated IGF-1 response.
• Endocrine regulation – study of feedback loops within the hypothalamus–pituitary axis.
• Body composition – exploratory studies into changes in fat and fat-free mass within experimental models.
• Repair and adaptation mechanisms – research into GH-related processes in muscle and tissue models.
• Synergistic peptide interaction – comparison of combined stimulation versus separate peptide application.

These observations are based on research data and do not constitute evidence of safety or effectiveness outside laboratory environments.

Safety and research context

CJC 1295 + Ipamorelin is not registered for therapeutic uses and falls outside regulated clinical use. The product is intended exclusively for professional research within controlled laboratory environments.

• For research purposes only (e.g. in vitro and analytical applications)
• Not intended for clinical or veterinary use
• Keep out of reach of unauthorized persons

Use outside a research context can lead to unpredictable risks and is considered irresponsible.

Summary

FIT PEPTIDES CJC 1295 + Ipamorelin is a research-grade peptide combination for professional laboratory research into combined GHRH and GHRP stimulation, GH and IGF-1 profiles, and endocrine regulation. The product aligns with other endocrine-targeted research peptides within the
Cceleste Peptides range and is intended exclusively for scientific and educational purposes.

Frequently asked questions about CJC 1295 + Ipamorelin

What is CJC 1295 + Ipamorelin?
It is a combination of two research peptides used to study growth hormone and IGF-1 release in research models.

What is this peptide combination being investigated for?
The combination is being investigated in relation to endocrine regulation, GH/IGF-1 dynamics, and hormonal feedback mechanisms.

Is CJC 1295 + Ipamorelin approved?
No, this peptide combination is not approved by regulatory authorities and is intended solely for research purposes.

Why are CJC 1295 and Ipamorelin combined?
Because they stimulate GH release via different receptor pathways, it is being investigated whether combined use produces a synergistic effect.

For which type of research is this combination suitable?
The combination is suitable for fundamental and applied endocrinological research, including hormone profiling and signaling pathway analysis.

Where does this product fit within the Cceleste Peptides range?
CJC 1295 + Ipamorelin falls within the category of endocrine signaling agents and forms a logical part of research into hormonal regulation.